Now showing items 1-15 of 15

    • Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. 

      Gengiah, Tanuja N.; Moosa, Atika.; Naidoo, Anushka.; Mansoor, Leila E. (Springer Verlag., 2013-10)
      Background: There are 34 million people living with human immunodeficiency virus (HIV) worldwide and each year this number increases. Until a vaccine is discovered, the prevention of new HIV infections remains an urgent ...
    • Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. 

      Archary, Derseree.; Rong, Rong.; Gordon, Michelle Lucille.; Boliar, Saikat.; Madiga, Maphuti C.; Gray, Elin S.; Dugast, Anne-Sophie.; Hermanus, Tandile.; Goulder, Philip.; Coovadia, Hoosen Mahomed.; Werner, Lise.; Morris, Lynn.; Alter, Galit.; Derdeyn, Cynthia A.; Ndung'u, Thumbi. (Elsevier., 2012-11-25)
      Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically ...
    • Comparison of viral env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. 

      Ping, Li-Hua.; Joseph, Sarah B.; Anderson, Jeffrey A.; Abrahams, Melissa-Rose.; Salazar-Gonzalez, Jesus F.; Kincer, Laura P.; Treurnicht, Florette.; Arney, Leslie.; Ojeda, Suany.; Zhang, Ming.; Keys, Jessica.; Potter, E. Lake.; Chu, Haitao.; Moore, Penny L.; Salazar-Gonzalez, Maria.; Iyer, Shilpa.; Jabara, Cassandra.; Kirchherr, Jennifer.; Mapanje, Clement.; Ngandu, Nobubelo.; Seoighe, Cathal.; Hoffman, Irving F.; Gao, Feng.; Tang, Yuyang.; Labranche, Celia.; Lee, Benhur.; Saville, Andrew.; Vermeulen, Marion.; Fiscus, Susan.; Morris, Lynn.; Abdool Karim, Salim Safurdeen.; Haynes, Barton F.; Shaw, George M.; Korber, Bette T.; Hahn, Beatrice H.; Cohen, Myron.; Montefiori, David C.; Williamson, Carolyn.; Swanstrom, Ronald. (American Society for Microbiology., 2013-04-24)
      Understanding human immunodeficiency virus type 1 (HIV-1) transmission is central to developing effective prevention strategies, including a vaccine.We compared phenotypic and genetic variation in HIV-1 env genes from ...
    • The development of CD4 binding site antibodies during HIV-1 infection. 

      Lynch, Rebecca M.; Tran, Lillian.; Louder, Mark K.; Schmidt, Stefan D.; Cohen, Myron.; DerSimonian, Rebecca.; Euler, Zelda.; Gray, Elin S.; Abdool Karim, Salim Safurdeen.; Kirchherr, Jennifer.; Montefiori, David C.; Sibeko, Sengeziwe.; Soderberg, Kelly.; Tomaras, Georgia D.; Yang, Zhi-Yong.; Nabel, Gary J.; Schuitemaker, Hanneke.; Morris, Lynn.; Haynes, Barton F.; Mascola, John R. (American Society for Microbiology., 2012-07)
      Broadly neutralizing antibodies to the CD4 binding site (CD4bs) of gp120 are generated by some HIV-1-infected individuals, but little is known about the prevalence and evolution of this antibody response during the course ...
    • Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape. 

      Moore, Penny L.; Gray, Elin S.; Wibmer, Constantinos Kurt.; Bhiman, Jinal N.; Nonyane, Molati.; Hermanus, Tandile.; Sheward, Daniel.; Bajimaya, Shringkhala.; Abrahams, Melissa-Rose.; Tumba, Nancy L.; Ping, Li-Hua.; Ngandu, Nobubelo.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Swanstrom, Ronald.; Seaman, Michael S.; Williamson, Carolyn.; Morris, Lynn. (Nature Publishing Group., 2012-11)
      Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine. Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been unsuccessful, a minority of individuals ...
    • HIV vaccines and immunity. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (Allergy Society of South Africa., 2003-06)
      No abstract available.
    • Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. 

      Moore, Penny L.; Sheward, Daniel.; Nonyane, Molati.; Ranchobe, Nthabeleng.; Hermanus, Tandile.; Gray, Elin S.; Abdool Karim, Salim Safurdeen.; Williamson, Carolyn.; Morris, Lynn. (American Society for Microbiology., 2013-02-13)
      Broadly cross-neutralizing (BCN) antibodies are likely to be critical for an effective HIV vaccine. However, the ontogeny of such antibodies and their relationship with autologous viral evolution is unclear. Here, we ...
    • Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. 

      Wecker, M.; Gilbert, Peter.; Russell, N.; Hural, J.; Allen, Mary.; Pensiero, M.; Chulay, J.; Chiu, Ya-Lin.; Abdool Karim, Salim Safurdeen.; Burke, D. S. (American Society for Microbiology., 2012-10)
      On the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, ...
    • Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. 

      Moore, Penny L.; Gray, Elin S.; Sheward, Daniel.; Madiga, Maphuti C.; Ranchobe, Nthabeleng.; Honnen, William J.; Nonyane, Molati.; Tumba, Nancy L.; Hermanus, Tandile.; Sibeko, Sengeziwe.; Mlisana, Koleka.; Abdool Karim, Salim Safurdeen.; Williamson, Carolyn.; Pinter, Abraham.; Morris, Lynn.; Lai, Zhong. (American Society for Microbiology., 2011-04)
      The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV vaccine field. We have identified a subtype C HIV-1-superinfected individual, CAP256, with high-level BCN activity, and ...
    • Preservation HIV-1–specific IFNg+ CD4+ T-Cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. 

      Mureithi, Marianne W.; Poole, Danielle.; Naranbhai, Vivek.; Reddy, Shabashini.; Mkhwanazi, Nompumelelo Prudence.; Sibeko, Sengeziwe.; Werner, Lise.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Ndung'u, Thumbi.; Altfeld, Marcus. (Lippincott Williams & Wilkins., 2011)
      Abstract: The Centre for the AIDS Program of Research in South Africa 004 trial demonstrated reduction of sexual HIV-1 acquisition in women using a vaginal microbicide containing tenofovir. A better understanding of the ...
    • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. 

      Abrahams, Melissa-Rose.; Anderson, Jeffrey A.; Giorgi, E. E.; Seoighe, Cathal.; Mlisana, Koleka.; Liu, Pinghuang.; Athreya, G. S.; Treurnicht, Florette.; Keele, Brandon F.; Wood, N.; Salazar-Gonzalez, Jesus F.; Bhattacharya, T.; Chu, Haitao.; Hoffman, Irving F.; Galvin, S.; Mapanje, Clement.; Kazembe, P.; Thebus, Ruwayida.; Fiscus, Susan.; Hide, Winston.; Cohen, Myron.; Abdool Karim, Salim Safurdeen.; Haynes, Barton F.; Shaw, George M.; Hahn, Beatrice H.; Korber, Bette T.; Swanstrom, Ronald.; Williamson, Carolyn. (American Society for Microbiology., 2009-04)
      Identifying the specific genetic characteristics of successfully transmitted variants may prove central to the development of effective vaccine and microbicide interventions. Although human immunodeficiency virus transmission ...
    • Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate Human Immunodeficiency Virus Type 1 vaccines. 

      Mascola, John R.; D'Souza, Patricia.; Gilbert, Peter.; Hahn, Beatrice H.; Haigwood, Nancy L.; Morris, Lynn.; Petropoulos, Christos J.; Polonis, Victoria R.; Sarzotti, Marcella.; Montefiori, David C. (American Society for Microbiology., 2005-08)
      No abstract available.
    • Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. 

      Gray, Glenda E.; Allen, Mary.; Moodie, Zoe.; Churchyard, Gavin J.; Bekker, Linda-Gail.; Nchabeleng, Maphoshane.; Mlisana, Koleka.; Metch, Barbara.; De Bruyn, Guy.; Latka, Mary H.; Roux, Surita.; Mathebula, Matsontso.; Naicker, Nivashnee.; Ducar, Constance.; Carter, Donald K.; Puren, Adrien.; Eaton, Niles.; McElrath, M. Julie.; Robertson, Michael.; Corey, Lawrence.; Kublin, James. (Elsevier., 2011-07)
      Background. The MRKAd5 HIV-1 gag/pol/nef subtype B vaccine was designed to elicit T-cell-mediated immune responses capable of providing complete or partial protection from HIV-1 infection or a decrease in viral load after ...
    • Topical microbicides - What's new? 

      Abdool Karim, Quarraisha.; Baxter, Cheryl.; Abdool Karim, Salim Safurdeen. (Lippincott Williams & Wilkins., 2013-07-01)
      Topical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and ...
    • Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. 

      Wibmer, Constantinos Kurt.; Bhiman, Jinal N.; Gray, Elin S.; Tumba, Nancy L.; Abdool Karim, Salim Safurdeen.; Williamson, Carolyn.; Morris, Lynn.; Moore, Penny L. (Plos., 2013-10-31)
      Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine. We previously identified a ...